IL-6 upregulates immunosuppressive cells, inhibits anti-tumor immune cells, or reduces their infiltration, constructing a highly immunosuppressive tumor microenvironment, potentially leading to ESCC progression and treatment resistance. This evidence concerns the gene IL6 and esophageal squamous cell carcinoma.